ERBB2 and neoplasm: Shoda et al. used droplet digital polymerase chain reaction and determined that the HER2 amplification status in circulating tumor DNA (ctDNA) is highly concordant with that of primary tumors, with a specificity of 0.733 and a sensitivity of 0.933 (40).